Perspectives in camptothecin development

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 6, 2002, Pages 837-844

  Dallavalle, Sabrina ^a   Merlini, Lucio ^a   Penco, Sergio ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Antitumour chemotherapy; Camptothecins (CPTs); Topoisomerase I inhibitors

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AFELETECAN; ANTINEOPLASTIC AGENT; BELOTECAN; BN 80927; BPN 1350; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DB 38; DB 67; DE 310; DIFLOMOTECAN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DX 8951 F; EXATECAN; GIMATECAN; HOMOCAMPTOTHECIN; IRINOTECAN; KARENITECIN; LACTONE; LIPOSOME; LURTOTECAN; PRODRUG; PROTHECAN; RUBITECAN; SILETECAN DERIVATIVE; ST 1472; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; LIPOPHILICITY; NONHUMAN; REVIEW;

EID: 0036078406     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.6.837     Document Type: Review

References (39)

1. Topoisomerase I poisons and suppressors as anticancer drugs
2. Mechanism of action of eukariotic DNA topoisomerase I and drugs targeted to the enzyme
3. Mechanism of action of camptothecin in The Camptothecins. Unfolding their Anti-Cancer potential
4. Antitumor inhibitors of DNA topoisomerases
5. Topoisomerase I inhibitors: Review and update
6. The cell cycle effects of camptothecin
7. Mechanism of action of camptothecin
8. Protocols for the treatment of human tumor xenografts with camptothecins
9. Camptothecin and its analogs: An overview of their potential in cancer therapeutics
10. Novel 7-substituted camptothecins with potent antitumor activity
11. Novel 7-Oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity
12. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin
13. The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high liphophilicity, improved human blood stability, and potent anticancer activity
14. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo
15. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer
16. Homocamptothecins: Synthesis and antitumor activity of novel E-ring modified camptothecin analogues
17. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties
18. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations
19. Structure-activity relationships of alkyl camptothecin esters
20. Modulation of camptothecin analogs in the treatment of cancer: A review
21. Polymer-bound camptothecin: Initial biodistribution and antitumour activity studies
22. Camptothecin delivery systems: The utility of aminoacid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs
23. Conjugation of camptothecins to poly-(L-glutamic acid)
24. The A-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f[III]: Pharmacokinetic evaluation in normal and tumor-bearing mice
25. Complete regression of xenografted human carcinomas by camptothecin analogue carboxymethyl dextran conjugate (T-0128)
26. Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents
27. Comparison of Topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
28. Lipid bilayer partitioning and stability of camptothecin drugs
29. BNP1350s (Karenitecin™) superior molecular characteristics: Enhanced therapeutic performance of novel lipophilic, lactone stable camptothecin analogues
30. Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA
31. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
32. The other camptothecins: Recent advances with camptothecin analogs other than irinotecan and topotecan
33. Homocamptothecin, an E-ring modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks
34. The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison
35. The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor
36. Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities
37. Novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line
38. Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells
39. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: A low-clearance liposomal formulation of lurtotecan